发布求助
文献互助 智能选刊 最新文献

Australian Prescriber最新文献

筛选
英文 中文
Practical guidance for stopping glucocorticoids. 停用糖皮质激素的实用指南。
IF 4.2
Australian Prescriber Pub Date : 2025-08-01 DOI: 10.18773/austprescr.2025.037
Faran Khalili, Morton G Burt
{"title":"Practical guidance for stopping glucocorticoids.","authors":"Faran Khalili, Morton G Burt","doi":"10.18773/austprescr.2025.037","DOIUrl":"10.18773/austprescr.2025.037","url":null,"abstract":"<p><p>Glucocorticoids can be stopped abruptly, without tapering, in patients prescribed them for less than 3 to 4 weeks. Prolonged glucocorticoid use (more than 3 to 4 weeks) can cause hypothalamic-pituitary-adrenal (HPA) axis suppression, necessitating gradual stopping (tapering) to prevent the consequences of adrenal insufficiency. For some patients on prolonged glucocorticoids, the dosage can be tapered and stopped without testing serum cortisol concentrations. For some patients on prolonged glucocorticoids, morning serum cortisol testing can be used to assess HPA axis recovery and guide glucocorticoid cessation. Further testing of the HPA axis, with an adrenocorticotrophic hormone stimulation test, and referral to endocrinology services may be required in patients with repeated low cortisol concentrations despite a prolonged period at a physiological glucocorticoid dose.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 4","pages":"116-121"},"PeriodicalIF":4.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378006/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Selpercatinib for RET fusion-positive non-small cell lung cancer. Selpercatinib治疗RET融合阳性非小细胞肺癌。
IF 4.2
Australian Prescriber Pub Date : 2025-08-01 DOI: 10.18773/austprescr.2025.033
{"title":"Selpercatinib for RET fusion-positive non-small cell lung cancer.","authors":"","doi":"10.18773/austprescr.2025.033","DOIUrl":"10.18773/austprescr.2025.033","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 4","pages":"151-152"},"PeriodicalIF":4.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378005/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144979115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aminoglycosides: an update on indications, dosing and monitoring. 氨基糖苷类：适应症、剂量和监测的最新情况。
IF 4.2
Australian Prescriber Pub Date : 2025-08-01 DOI: 10.18773/austprescr.2025.038
Hazel Moore, Daniel Yeoh, Carly Hughes, Edward Raby, Indy Sandaradura
{"title":"Aminoglycosides: an update on indications, dosing and monitoring.","authors":"Hazel Moore, Daniel Yeoh, Carly Hughes, Edward Raby, Indy Sandaradura","doi":"10.18773/austprescr.2025.038","DOIUrl":"10.18773/austprescr.2025.038","url":null,"abstract":"<p><p>Aminoglycosides (gentamicin, tobramycin and amikacin) are highly effective parenteral drugs commonly used as initial empirical therapy of serious Gram-negative infections. They have rapid bactericidal activity and relatively low rates of resistance in Australia compared with other antibiotics used to manage Gram-negative infections. Therapeutic Guidelines: Antibiotic was updated in March 2025 and provides new guidance on the role of aminoglycosides, optimised dosing, and drug selection. The guidelines now recommend that dosing in adults is based on lean body weight, and provide calculators to assist with dose calculations. Therapeutic drug monitoring is required when aminoglycoside therapy is expected to continue beyond 48 hours; monitoring the area under the aminoglycoside concentration-time curve is recommended in adults.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 4","pages":"133-138"},"PeriodicalIF":4.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144979835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COX-2 selective nonsteroidal anti-inflammatory drugs: what is their place in managing dental pain? COX-2选择性非甾体抗炎药：它们在治疗牙痛中的作用是什么？
IF 4.3
Australian Prescriber Pub Date : 2025-08-01 DOI: 10.18773/austprescr.2025.036
Geraldine Moses
{"title":"COX-2 selective nonsteroidal anti-inflammatory drugs: what is their place in managing dental pain?","authors":"Geraldine Moses","doi":"10.18773/austprescr.2025.036","DOIUrl":"10.18773/austprescr.2025.036","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 4","pages":"145-146"},"PeriodicalIF":4.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378000/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144979798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Update on long- and short-acting contraceptive methods. 长效和短效避孕方法的最新情况。
IF 3.4
Australian Prescriber Pub Date : 2025-06-01 DOI: 10.18773/austprescr.2025.023
Emma Mason, Kirsten Black
{"title":"Update on long- and short-acting contraceptive methods.","authors":"Emma Mason, Kirsten Black","doi":"10.18773/austprescr.2025.023","DOIUrl":"10.18773/austprescr.2025.023","url":null,"abstract":"<p><p>Long-acting reversible contraceptive methods, including the contraceptive implant and intrauterine devices, are highly effective and cost-effective options for women who have no specific contraindications. Long-acting reversible contraceptives are more effective at reducing unintended pregnancy than short-acting contraceptives. Short-acting contraceptive methods consist of combined hormonal contraception (e.g. the combined oral contraceptive pill, vaginal ring), progestogen-only pills, and the progestogen-containing contraceptive injection. Choice of contraception is based on factors such as medical eligibility (i.e. precautions, contraindications), patient preference and reproductive life stage. Counselling patients on the benefits and risks of all contraceptive methods is important for informed decision-making. Regular contraceptive review can allow for patient education and monitoring of adverse effects.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 3","pages":"72-81"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psoriasis: an update on topical and systemic therapies. 牛皮癣：局部和全身治疗的最新进展。
IF 3.4
Australian Prescriber Pub Date : 2025-06-01 DOI: 10.18773/austprescr.2025.026
Jonathan J Chan
{"title":"Psoriasis: an update on topical and systemic therapies.","authors":"Jonathan J Chan","doi":"10.18773/austprescr.2025.026","DOIUrl":"10.18773/austprescr.2025.026","url":null,"abstract":"<p><p>Psoriasis is an immune-mediated inflammatory disease with a genetic predisposition. Although manifesting predominantly as a hyperproliferative skin disorder, psoriasis is a systemic disease associated with a range of comorbidities including arthritis, cardiovascular disease and depression. Educating the patient that psoriasis is chronic and that there are possible comorbidities is paramount. Patients with a limited number of plaques and no systemic symptoms may be managed with intermittent use of topical therapies. Those with more extensive or debilitating disease may require phototherapy or systemic medicines such as methotrexate or one of the newer targeted therapies. Newer systemic therapies, including oral medicines and injectable biologics, can only be used following unsuccessful treatment with traditional therapies such as methotrexate and phototherapy. Biologic therapies for psoriasis offer the possibility of near-complete symptom resolution in people with psoriatic disease.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 3","pages":"87-92"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
More dual labelled medicines transition to sole names. 更多的双重标签药物转变为单一名称。
IF 3.4
Australian Prescriber Pub Date : 2025-06-01 DOI: 10.18773/austprescr.2025.022
{"title":"More dual labelled medicines transition to sole names.","authors":"","doi":"10.18773/austprescr.2025.022","DOIUrl":"10.18773/austprescr.2025.022","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 3","pages":"106"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spesolimab for generalised pustular psoriasis. Spesolimab治疗全身性脓疱性银屑病。
IF 3.4
Australian Prescriber Pub Date : 2025-06-01 DOI: 10.18773/austprescr.2025.025
{"title":"Spesolimab for generalised pustular psoriasis.","authors":"","doi":"10.18773/austprescr.2025.025","DOIUrl":"10.18773/austprescr.2025.025","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 3","pages":"109-110"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187476/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medicines used in the treatment of opioid dependence. 用于治疗阿片类药物依赖的药物。
IF 4.2
Australian Prescriber Pub Date : 2025-06-01 DOI: 10.18773/austprescr.2025.028
Hester Hk Wilson, Jillian Kanck
{"title":"Medicines used in the treatment of opioid dependence.","authors":"Hester Hk Wilson, Jillian Kanck","doi":"10.18773/austprescr.2025.028","DOIUrl":"10.18773/austprescr.2025.028","url":null,"abstract":"<p><p>Opioid dependence is a chronic condition that can lead to significant harm if left untreated. People who experience opioid dependence and the treatments themselves are highly stigmatised. Person-centred trauma-informed services are critical to therapeutic engagement and effectiveness. Buprenorphine and methadone are highly effective, evidence-based medicines for opioid dependence. In recent years, long-acting injectable buprenorphine has emerged as a safe and effective treatment option, offering flexible weekly or monthly dosing. The long-term treatment of opioid dependence can be undertaken in primary care settings. General practitioner and nurse practitioner prescribing, and community pharmacist dispensing, are essential for ongoing care. Australian jurisdictions have differing regulations that guide the prescribing of medicines for opioid dependence. Health professionals should be familiar with their local jurisdiction's guidelines as well as the national guidelines. Drug and alcohol telephone services are available in each jurisdiction and can provide advice to health professionals.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 3","pages":"98-105"},"PeriodicalIF":4.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187472/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Semaglutide for cardiovascular risk reduction in people who are overweight or have obesity without diabetes (new indication). 西马鲁肽用于超重或无糖尿病的肥胖人群心血管风险降低（新适应症）。
IF 3.4
Australian Prescriber Pub Date : 2025-06-01 DOI: 10.18773/austprescr.2025.024
{"title":"Semaglutide for cardiovascular risk reduction in people who are overweight or have obesity without diabetes (new indication).","authors":"","doi":"10.18773/austprescr.2025.024","DOIUrl":"10.18773/austprescr.2025.024","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 3","pages":"107-108"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187477/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书